UPC APP 18039/2025

—·EP2279254 +1 more: NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Sonstige prozessuale
Parteien: Kläger
Arbutus Biopharma Corporation
Genevant Sciences GmbH
Vertreter: Markus van Gardingen
Beklagte
Moderna Belgium S.R.L.
Moderna Denmark ApS
Moderna Portugal Unipessoal LDA
Moderna Poland SP. Z.O.O.
Moderna Netherlands B.V.
Moderna Biotech UK Limited
Moderna Italy S.R.L.
Moderna France SASU
Moderna Biotech Spain SL
Moderna Germany GmbH
Moderna Sweden AB
Moderna Norway AS
ModernaTX, Inc.
Moderna, Inc.
Moderna Switzerland GmbH
Vertreter: Ruben Laddé; Joachim Renken
Division: The Hague LD
Richter: —
Technology: Biotechnology
Sprache: —
Erste Entscheidung: 17. Apr. 2025

Entscheidungen

2025-04-17
Generic application
The Hague Local Division issued a procedural order rejecting Moderna defendants' requests to extend the deadline for filing preliminary objections and the Statement of Defence under R. 333 RoP, while setting a single consolidated deadline for all Moderna group defendants to file one joint Statement of Defence in the Arbutus/Genevant v. Moderna infringement proceedings (UPC_CFI_191-192/2025).
Rechtsfragen:Deadline for filing preliminary objections and Statement of DefenceStreamlining procedure for corporate group defendants (R. 333 RoP)Service of process on multiple international defendantsExpeditious proceedings in pharmaceutical infringement

Dokumente